Show simple item record

dc.contributor.authorKraby, Maria Ryssdal
dc.contributor.authorOpdahl, Signe
dc.contributor.authorAkslen, Lars A.
dc.contributor.authorBofin, Anna M.
dc.date.accessioned2019-02-22T08:30:06Z
dc.date.available2019-02-22T08:30:06Z
dc.date.created2017-03-14T08:25:44Z
dc.date.issued2017
dc.identifier.citationJournal of Clinical Pathology. 2017, 70 (9), 766-774.nb_NO
dc.identifier.issn0021-9746
dc.identifier.urihttp://hdl.handle.net/11250/2586905
dc.description.abstractAims Microvessel density (MVD), proliferating MVD (pMVD) and vascular proliferation index (VPI) are methods used to quantify tumour vascularity in histopathological sections. In this study, we assessed MVD, pMVD and VPI in non-luminal subtypes of breast cancer. Differences between subtypes were studied, and the prognostic value of each method was assessed. Methods All non-luminal subtypes (61 basal phenotype (BP), 60 human epidermal growth factor receptor 2 (HER2) type and 30 five negative phenotype (5NP)) were selected from a series comprising 909 cases of breast cancer. Sections were stained for Ki67 and von Willebrand factor. Associations between MVD, pMVD and VPI, molecular subtypes and prognosis were studied. Results MVD was highest in 5NP (Δ54.3 microvessels/mm2 compared with BP, 95% CI 30.3 to 78.3), whereas no clear difference was found between HER2 type and BP (Δ8.8 microvessels/mm2, 95% CI −9.6 to 27.1). pMVD and VPI did not differ between subtypes. For MVD, HR was 1.07 (95% CI 1.03 to 1.11) per 10 vessel increase and 1.9 (95% CI 1.2 to 3.1) if MVD was greater than median value. High MVD was associated with poor prognosis in the HER2 type (HR 1.07 (95% CI 1.02 to 1.12)) and 5NP (HR 1.13 (95% CI 1.03 to 1.23)), but not in BP (HR 1.04 (95% CI 0.94 to 1.14) per 10 vessel increase). pMVD and VPI were not associated with prognosis. Conclusions MVD appears to be an independent prognostic factor in HER2 and 5NP subtypes of breast cancer, where high MVD is associated with poor survival. MVD was higher in the 5NP compared with both BP and HER2 type.nb_NO
dc.language.isoengnb_NO
dc.publisherBMJ Publishing Groupnb_NO
dc.rightsNavngivelse-Ikkekommersiell 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/deed.no*
dc.titleQuantifying tumour vascularity in non-luminal breast cancersnb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionacceptedVersionnb_NO
dc.source.pagenumber766-774nb_NO
dc.source.volume70nb_NO
dc.source.journalJournal of Clinical Pathologynb_NO
dc.source.issue9nb_NO
dc.identifier.doi10.1136/jclinpath-2016-204208
dc.identifier.cristin1458028
dc.description.localcode© 2017. This is the authors’ accepted and refereed manuscript to the article. This manuscript version is made available under the CC-BY-NC 4.0 license http://creativecommons.org/licenses/by-nc/4.0/nb_NO
cristin.unitcode194,65,15,0
cristin.unitcode194,65,20,0
cristin.unitnameInstitutt for klinisk og molekylær medisin
cristin.unitnameInstitutt for samfunnsmedisin og sykepleie
cristin.ispublishedtrue
cristin.fulltextpostprint
cristin.qualitycode1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse-Ikkekommersiell 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse-Ikkekommersiell 4.0 Internasjonal